This year on Sunday we have this session on endothelial injury syndromes in hematology. Our team is really trying to unify these syndromes into one term. This is hard and maybe we cannot really put everything into one basket. But I think it is really important for clinicians and researchers to try to unify the pathophysiology of some syndromes so that we can address common things like the clinical presentation or even some biomarkers that may be common across syndromes...
This year on Sunday we have this session on endothelial injury syndromes in hematology. Our team is really trying to unify these syndromes into one term. This is hard and maybe we cannot really put everything into one basket. But I think it is really important for clinicians and researchers to try to unify the pathophysiology of some syndromes so that we can address common things like the clinical presentation or even some biomarkers that may be common across syndromes. But also introducing, of course, the personalized treatment into our algorithms. So this session, I am the chair of this session. I’m very happy to chair Professor Pouenac from Germany and Professor Rambaldi from Italy. They’re both very well-known experts, especially in transplant, but they’re also translational researchers really trying to bring innovative tools and biomarkers into our patients’ everyday life. The session will focus mostly on HSCT-TMA or thrombotic microangiopathy post-transplant and other transplant complications like VOD or also called SOS VOD and potentially other more rare syndromes that we want really to recognize in our patients and potentially create also guidelines or consensus documents for them in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
